Literature DB >> 6507057

Estriol: absorption after long-term vaginal treatment and gastrointestinal absorption as influenced by a meal.

G Heimer, D Englund.   

Abstract

This study was designed to evaluate the vaginal absorption of estriol when given as a 21-day treatment. Vaginal absorption was compared with the oral absorption of a known estriol preparation (TriovexR, Leo AB, Sweden). One mg of estriol was administered intravaginally once a day for 21 days to 6 menopausal women. Plasma concentrations of unconjugated estriol were measured by a specific RIA-method at frequent intervals during 24 hours on the first and 21st day of treatment. One month later, 10 mg of estriol was given once orally and plasma estriol concentrations were measured in the same way. At vaginal administration, the absorption of estriol was very effective. When measured on the 21st day, the absorption had declined significantly but was still nearly in the same range as after oral administration of 10 mg of estriol. At oral administration, there was an initial plasma estriol elevation for 3 hours only followed by a second one immediately postprandially. It is concluded that estriol is readily absorbed from the vagina, but the absorption does decline significantly during prolonged treatment. A large single oral dose of estriol provides initially a high plasma estriol concentration but also a second one induced by eating a meal, possibly indicating an enterohepatic recirculation of estriol.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6507057     DOI: 10.3109/00016348409156720

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  4 in total

1.  A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aromatase Inhibitor in the Adjuvant Setting.

Authors:  Pedro Sánchez-Rovira; Angelica Lindén Hirschberg; Miguel Gil-Gil; Begoña Bermejo-De Las Heras; Concepción Nieto-Magro
Journal:  Oncologist       Date:  2020-06-09

2.  Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study.

Authors:  Lena U Rosenberg; Cecilia Magnusson; Emma Lindström; Sara Wedrén; Per Hall; Paul W Dickman
Journal:  Breast Cancer Res       Date:  2006-02-17       Impact factor: 6.466

3.  Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study.

Authors:  Gilbert Donders; Patrick Neven; Maximilian Moegele; Anneleen Lintermans; Gert Bellen; Valdas Prasauskas; Philipp Grob; Olaf Ortmann; Stefan Buchholz
Journal:  Breast Cancer Res Treat       Date:  2014-04-10       Impact factor: 4.872

Review 4.  Local oestrogen for vaginal atrophy in postmenopausal women.

Authors:  Anne Lethaby; Reuben Olugbenga Ayeleke; Helen Roberts
Journal:  Cochrane Database Syst Rev       Date:  2016-08-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.